北京若生智能科技有限公司
Drug Database
BE

bevacizumab (BP 01 / Bevqolva / BP01)

✓ Approved

Aurobindo Pharma Limited · VEGFA · 单克隆抗体

什么是 bevacizumab？

bevacizumab 是一种单克隆抗体，由Aurobindo Pharma Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名BP 01, Bevqolva, BP01
公司Aurobindo Pharma Limited
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Aurobindo Pharma Limited

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Renal cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Colorectal cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedClinical and translational radiation oncology2026-10-27

Longitudinal tumor response dynamics after staged gamma knife radiosurgery combined with bevacizumab in sporadic vestibular schwannoma.

Peng Zeyu Z, Wang Shangbo S, Cao Jiao-Jiao JJ, Zhang Hongchi H et al.

Vestibular schwannomas (VSs) are benign tumors of the eighth cranial nerve. Although Gamma Knife radiosurgery (GKRS) achieves durable tumor control, delayed regression and pseudoprogression remain clinical challenges. Staged GKRS combined with bevacizumab may alter post-radiosurgical tumor response patterns. To compare longitudinal tumor response, pseudoprogression, and clinical outcomes between staged GKRS combined with bevacizumab and single-session GKRS alone in sporadic VSs. We retrospectively reviewed 72 patients with sporadic VSs: 49 treated with staged GKRS plus bevacizumab and 23 with single-session GKRS alone. Longitudinal tumor volume changes were analyzed using multivariable linear mixed-effects models, while early volumetric enlargement was evaluated using Kaplan-Meier estimates and Cox proportional hazards models. Compared with GKRS alone, staged GKRS plus bevacizumab showed significantly different response trajectories (treatment-by-time interaction, P < 0.001), with earlier and sustained regression. Greater tumor reduction was observed from 3 to 36 months (all adjusted P < 0.05). Early volumetric enlargement (>10%) occurred in 14.3% versus 60.9% of patients (HR, 0.16; 95% CI, 0.06-0.40; P < 0.001). Pseudoprogression occurred in 4.1% versus 17.4% of patients, without statistical significance (P = 0.078). Cystic tumor composition was independently associated with greater regression. BEV-related adverse events were mild and manageable. Staged GKRS combined with bevacizumab was associated with earlier, more sustained tumor regression and a lower risk of early post-treatment enlargement in sporadic VSs. Larger baseline tumor volume and cystic composition were associated with greater regression. Pseudoprogression was numerically less frequent, although the difference was not statistically significant. ChiCTR2600131856 (Chinese Clinical Trial Registry).

PMID 42936495
阅读全文 →
PubMedFrontiers in immunology2026-10-27

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study.

Ishida Masaki M, Yamada Tadaaki T, Kamada Riko R, Hibino Makoto M et al.

Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung cancer is associated with a poor prognosis, underscoring the need for effective pharmacological treatments. An exploratory subgroup analysis of IMpower150 suggested potential clinical benefit of the atezolizumab-containing regimen in KRAS-mutant non-squamous NSCLC, although prospective data remain limited. We prospectively evaluated its efficacy and safety and performed exploratory biomarker analyses. The study cohort comprised patients with advanced or recurrent KRAS-mutant non-squamous NSCLC scheduled to receive ICI plus bevacizumab-based chemotherapy at 10 Japanese institutions between January 2023 and December 2024. The primary endpoint was progression-free survival (PFS). Secondary endpoints included disease control rate (DCR), objective response rate (ORR), overall survival (OS), and safety. Associations between baseline serum levels of vascular endothelial growth factor (VEGF)-A and VEGF-D and treatment outcomes were explored in patients with available pretreatment samples. Of 22 enrolled patients, 21 received treatment and were analyzed for efficacy and safety; 17 were analyzed for serum biomarkers. All patients received atezolizumab, bevacizumab, carboplatin, and paclitaxel. The median PFS and OS were 6.0 and 17.1 months, respectively. Among 19 patients with measurable disease, the ORR was 42.1%, and the DCR was 68.4%. Grade ≥3 hematologic and non-hematologic adverse events occurred in 33.3% and 47.6% of patients, respectively. Baseline serum VEGF-A and VEGF-D levels were not significantly associated with the treatment outcomes. ICI plus bevacizumab-based chemotherapy showed an ORR of 42.1%, a median PFS of 6.0 months, and a median OS of 17.1 months in patients with KRAS-mutant non-squamous NSCLC. Given the small sample size and single-arm design, these findings should be considered descriptive and hypothesis-generating. Pretreatment serum VEGF-A and VEGF-D levels were not significantly associated with clinical outcomes, although limited statistical power precludes definitive conclusions. Larger comparative studies with comprehensive molecular profiling are warranted.

PMID 42935986
阅读全文 →
PubMedJournal of clinical medicine2026-10-27

The Impact of Multiple Biologic Failures on Surgical Outcomes: A Retrospective Cohort Study of Elective Subtotal Colectomy for Ulcerative Colitis.

Rudnicki Yaron Y, Jeffery Jaxson R JR, Derakshani Donya D, Mathis Kellie L KL

Background: Subtotal colectomy (STC) with end ileostomy (EI) is usually the first surgical stage for patients with ulcerative colitis (UC) who fail medical treatment, most often with biological agents. Is there a difference in surgical outcome after failure of one or two biologicals vs. three or four? Methods: A retrospective study of all patients who underwent STC with EI for UC (5-2018 to 1-2022). After excluding emergent cases, the elective cohort was divided into patients who failed 1-2 biologicals (group 1-2) vs. patients who failed 3-4 biologicals (group 3-4), and surgical outcomes were compared. Data collected included patients' demographics, preoperative clinical manifestations, and operative and postoperative outcomes. Results: Ninety-eight patients underwent STC for UC, and of them, 53 were elective. Thirty patients failed 1-2 biologics (group 1-2), and 23 failed 3-4 biologics (group 3-4). The groups were similar in average age (37.6 ± 11 vs. 32.7 ± 10), BMI (26.7 ± 6 vs. 27.7 ± 7), number of years with UC (9.5 ± 9 vs. 9 ± 8), rate of steroid dependence (20 (67%) vs. 13 (57%)) but differed in sex; there were 25 (83%) males in group 1-2, and 8 (35%) in group 3-4 (p < 0.01). The operative approaches were similar, as was the operative time (217 ± 74 vs. 210 ± 79 min). The length of hospital stay was 3.2 ± 1 days for group 1-2 and 5 ± 6 days for group 3-4 (p = 0.14). Postoperative complications were seen in 10 patients (33%) vs. 7 patients (30%) (p = 0.82), and of them, two (7%) and two (9%) (p = 0.82) had Venous thromboembolism (VTE), respectively. Only 20 patients (67%) in group 1-2 and 16 patients (70%) in group 3-4 (p = 0.82) progressed to a second stage of an Ileoanal pouch (IPAA) at 11.1 ± 4 and 9.2 ± 2 months, respectively. The overall average follow-up time was 41.1 months. Conclusions: Ulcerative Colitis patients who fail 3-4 biological agents and choose to go to elective STC with EI have very similar surgical outcomes compared to patients who choose elective surgery after failing only 1-2 biological agents in the same time span of known disease. UC patients with severe colitis and poor quality of life who fail two lines of biological agents may be better off electing surgical treatment than failing more biologics and then going to surgery. On the other hand, patients who try 3-4 biologics may expect no worse surgical outcomes than after 1-2 biologics.

PMID 42941636
阅读全文 →
PubMedCancers2026-10-27

Baseline Host Biomarkers and Six-Month Sustained Drug-Free Status After Atezolizumab-Bevacizumab for Hepatocellular Carcinoma: Exploratory Clinical Stratification Using PAN-DF Score.

Iino Chikara C, Abe Tamami T, Endo Kei K, Fujiwara Yudai Y et al.

Background/Objectives: Sustained drug-free status is an emerging milestone after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. We examined baseline host biomarkers associated with achievement of 6-month sustained drug-free status and evaluated a composite stratification score. Methods: This multicentre retrospective study included patients treated with atezolizumab plus bevacizumab. The endpoint required systemic therapy discontinuation after complete response or no viable disease, followed by at least 6 months without viable or recurrent hepatocellular carcinoma and sustained normalization of initially elevated tumour markers. The PAN-DF score (preserved hepatic reserve, altered immune-inflammatory status, and nutritional-immune reserve for achieving drug-free status) combined modified albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, and prognostic nutritional index. Results: Among 655 patients, 25 achieved the endpoint; median post-discontinuation follow-up was 533 days. In the complete-case cohort (n = 473; 17 events), achievement rates were 0.0%, 2.9%, 3.7%, and 13.6% for scores 0-3. Each one-point increase was associated with higher odds of achievement (odds ratio 2.90, 95% confidence interval 1.51-5.55; p = 0.001), and the area under the curve was 0.719. The examined baseline tumour-related factors were not significantly associated with the primary endpoint, and the examined host-related factors were not associated with objective response. Conclusions: Selected baseline host biomarkers were associated with achievement of 6-month sustained drug-free status. PAN-DF stratified the observed probability of this outcome and may help identify patient groups with a relatively higher likelihood of a sustained drug-free state, supporting early multidisciplinary planning.

PMID 42938898
阅读全文 →
PubMedAnnals of thoracic medicine2026-10-27

Real-world effectiveness and clinical outcomes of biologic therapy in severe asthma: A single-center experience from the United Arab Emirates.

Ayoob Muhammed Anas MA, Al Mazrooei Khulood Abdulla Salem KAS, Al Nahdi Najla Salem Ahmed NSA

Severe asthma remains a significant global healthcare challenge, contributing disproportionately to morbidity and healthcare utilisation despite guideline-based therapy. In the Middle East, a study reported a severe asthma prevalence of 6.4% regionally and 7.6% in Gulf countries. Affected individuals experience persistent symptoms, reduced quality of life, and frequent exacerbations. While biologic therapies have transformed the management of severe asthma by targeting specific inflammatory pathways, real-world data from the Gulf region remain limited. This study evaluates the real-world effectiveness of biologic therapies at a tertiary care center. This retrospective observational cohort study included adults with severe asthma receiving biologic therapy between 2020 and 2025. Exacerbation frequency, Asthma Control Test (ACT) scores, pulmonary function, biomarkers, and hospitalization rates were assessed at baseline and 12 months. Biologics evaluated included mepolizumab, benralizumab, dupilumab, tezepelumab, and omalizumab. In 114 patients with severe asthma, biologic therapy led to significant improvements in all measured domains. Annual exacerbations decreased by 52%, and ACT scores improved from 11.9 to 18.1 (P < 0.001). Blood eosinophil counts declined by 54%, fractional exhaled nitric oxide by 37%, hospitalization rates by 47%, and steroid courses by 48% (all P < 0.001). Forced expiratory volume in 1 s also improved significantly. While dupilumab showed numerically greater improvements, these differences were not statistically significant after adjustment. Adverse events were infrequent (8.8%) and mostly mild. Biologic therapy significantly improved clinical outcomes, reduced exacerbations, decreased corticosteroid exposure, and suppressed type 2 inflammatory biomarkers in a real-world UAE cohort, supporting the use of precision biologics in Middle Eastern populations and highlighting the need for larger prospective regional studies.

PMID 42936336
阅读全文 →
PubMedElectrophoresis2026-10-27

From Enrichment to Insight: Leveraging Preparative cIEF Enrichments and Characterization to Support Data-Driven Integration Practices for cIEF-based Analytics.

Rao Ramya R, Herrmann Dominik D, Kelley Seamus S, Cotham Victoria V et al.

Biologics such as therapeutic monoclonal antibodies (mAbs) require comprehensive chemistry, manufacturing, and control (CMC) strategies to ensure product safety, efficacy, and consistency. Among these strategies is the comprehensive assessment of product-related variants arising throughout the product development lifecycle. Routine capillary isoelectric focusing (cIEF) analysis of a therapeutic IgG molecule (mAb1) revealed a novel, poorly resolved basic peak at varying abundance across several lots, prompting an investigation. A preparative cIEF-based fractionation strategy with downstream identity characterization by both intact and site-specific mass spectrometry was performed, revealing several basic posttranslational modifications (PTMs), including incomplete N-terminal pyroglutamate conversion and Fc methionine oxidation. These PTMs were ultimately deemed low risk due to their overall low abundance in the unfractionated control and lack of impact on target binding, informing data-driven decision-making for cIEF integration at product release.

PMID 42934941
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab